Lord, Abbett & Co
MCRB icon

Lord, Abbett & Co’s Seres Therapeutics MCRB Stock Holding History

Lord, Abbett & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-43,706
Closed -$20.8M – 674
2021
Q2 		$20.8M Buy
43,706
+8,704
+25% +$3.67M 0.05% 409
2021
Q1 		$14.4M Sell
35,002
-31,393
-47% -$14.5M 0.04% 465
2020
Q4 		$32.5M Buy
66,395
+50,348
+314% +$29.5M 0.09% 335
2020
Q3 		$9.09M Buy
+16,047
New +$5.34M 0.03% 484
2016
Q1 		– Sell
-4,144
Closed -$2.91M – 917
2015
Q4 		$2.91M Sell
4,144
-7,593
-65% -$4.99M 0.01% 806
2015
Q3 		$6.96M Buy
11,737
+3,737
+47% +$3.05M 0.02% 667
2015
Q2 		$6.64M Buy
+8,000
New +$6.98M 0.02% 718

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co's MCRB Position: Q3 2021 in Review

Lord, Abbett & Co sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 43,706 shares — an estimated $20.8M sold.

Lord, Abbett & Co first reported a position in MCRB in Q2 2015 and held it in 7 quarters. The position peaked at $32.5M in Q4 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Lord, Abbett & Co reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 43,706 Seres Therapeutics shares in Q3 2021, an estimated $20.8M.
  • Lord, Abbett & Co first reported a position in Seres Therapeutics in Q2 2015 and held it in 7 quarters.
  • Lord, Abbett & Co's Seres Therapeutics position peaked at $32.5M in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Lord, Abbett & Co's 13F filing for Q3 2021, filed 9 Nov 2021.